Briggs Morrison - 07 Feb 2024 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Reporting relationship: Director
Issuer ticker: SNDX
Reported as of: 07 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2024, 16:04:08 UTC
Prior SEC filing: 10 Aug 2023
Next SEC filing: 24 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael A. Metzger, Attorney-in-fact

Key filing fact

Briggs Morrison filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 09 Feb 2024.

Key facts

This page summarizes Briggs Morrison's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Feb 2024, 16:04.

Change

Previous filing in this sequence was filed on 10 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNDX transaction

Common Stock

Award

Transaction value: $0
Shares: +17,000
Change %: +95%
Price: $0.000000
Shares after: 34,836
Date: 07 Feb 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.